Reconcile DSIP and emideltide names
FDA identifies emideltide as DSIP and describes missing safety information for the proposed route. A sleep-related name does not establish a supported clinical outcome.
Documentation to request
Request identity documentation using both names where applicable, and compare the vial and spray as different finished preparations.
Regulatory context: FDA: substance-specific safety concerns. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.
Related guidance: Non-clinical protocol review checklist. These references support a review, not a treatment recommendation or supply authorization.